Education
About Us
Working with TipRanks
Follow Us
Kyverna Therapeutics, Inc. (KYTX)
NASDAQ:KYTX
KYTX Stock Chart & Stats
$8.02
-$0.14(-3.63%)
At close: 4:00 PM EST
$8.02
-$0.14(-3.63%)
Day’s Range― - ―
52-Week Range$1.78 - $13.67
Previous CloseN/A
Volume87.17K
Average Volume (3M)702.06K
Market Cap
$458.18M
Enterprise Value$358.85M
Total Cash (Recent Filing)$171.14M
Total Debt (Recent Filing)$5.02M
Price to Earnings (P/E)―
Beta1.65
Next Earnings
Apr 01, 2026EPS Estimate
-0.85Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.85
Shares Outstanding57,129,500
10 Day Avg. Volume504,173
30 Day Avg. Volume702,059
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)0.54
Price to Sales (P/S)0.00
P/FCF Ratio-1.23
Enterprise Value/Market Cap0.78
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-179.97
Enterprise Value/Ebitda-2.26
Forecast
1Y Price Target
$29.50Price Target Upside267.83% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)-3.47
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
BLA Filing And Approval PotentialAnalyst considers the planned BLA submission for miv-cel in stiff person syndrome a major catalyst, since approval could establish the therapy as the first FDA-approved CAR-T for an autoimmune condition and unlock a new commercial market.
Clinical Efficacy And Functional GainsAnalyst highlights that pivotal KYSA-8 results showed strong efficacy and objective patient improvements, including many patients no longer needing walking aids, which supports confidence in miv-cel's meaningful clinical benefit.
Management Execution And Pipeline ProgressAnalyst notes that early availability of trial readouts and a confirmed IND for a second program reflect effective management execution and a rapid whole-blood manufacturing approach that could accelerate development and commercialization.
Bears Say
Regulatory UncertaintyAnalyst warns that broader regulatory uncertainty is dampening stock momentum, reflecting potential unpredictability around approval timing and payer or access decisions.
Kyverna Therapeutics, Inc. News
KYTX FAQ
What was Kyverna Therapeutics, Inc.’s price range in the past 12 months?
Kyverna Therapeutics, Inc. lowest stock price was $1.78 and its highest was $13.67 in the past 12 months.
What is Kyverna Therapeutics, Inc.’s market cap?
Kyverna Therapeutics, Inc.’s market cap is $458.18M.
When is Kyverna Therapeutics, Inc.’s upcoming earnings report date?
Kyverna Therapeutics, Inc.’s upcoming earnings report date is Apr 01, 2026 which is in 27 days.
How were Kyverna Therapeutics, Inc.’s earnings last quarter?
Kyverna Therapeutics, Inc. released its earnings results on Nov 12, 2025. The company reported -$0.85 earnings per share for the quarter, beating the consensus estimate of -$0.971 by $0.121.
Is Kyverna Therapeutics, Inc. overvalued?
According to Wall Street analysts Kyverna Therapeutics, Inc.’s price is currently Undervalued.
Does Kyverna Therapeutics, Inc. pay dividends?
Kyverna Therapeutics, Inc. does not currently pay dividends.
What is Kyverna Therapeutics, Inc.’s EPS estimate?
Kyverna Therapeutics, Inc.’s EPS estimate is -0.85.
How many shares outstanding does Kyverna Therapeutics, Inc. have?
Kyverna Therapeutics, Inc. has 57,129,500 shares outstanding.
What happened to Kyverna Therapeutics, Inc.’s price movement after its last earnings report?
Kyverna Therapeutics, Inc. reported an EPS of -$0.85 in its last earnings report, beating expectations of -$0.971. Following the earnings report the stock price went down -11.596%.
Which hedge fund is a major shareholder of Kyverna Therapeutics, Inc.?
Currently, no hedge funds are holding shares in KYTX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Kyverna Therapeutics, Inc. Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$29.50 (267.83% Upside)
$29.50 (267.83% Upside)
Blogger Sentiment
Bullish
KYTX Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 2.6M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $2.0M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Positive
Last 7 Days ▼ 0.3%
Last 30 Days ▲ 0.3%
Last 30 Days ▲ 0.3%
Technicals
SMA
Positive
20 days / 200 days
Momentum
209.65%
12-Months-Change
Fundamentals
Return on Equity
-70.82%
Trailing 12-Months
Asset Growth
-44.82%
Trailing 12-Months
Company Description
Kyverna Therapeutics, Inc.
Kyverna Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing cell therapies for patients suffering from autoimmune diseases. Its lead product candidate is KYV-101, an autologous CD19 CAR T-cell product candidate for the treatment of patients with lupus nephritis and systemic sclerosis that is in Phase I clinical trial; and for myasthenia gravis and multiple sclerosis that is in Phase II clinical trial. The company is also developing KYV-201, an allogeneic CD19 CAR T-cell product candidate that is in preclinical stage to treat multiple autoimmune diseases. In addition, it is developing product candidates to treat other autoimmune diseases, such as inflammatory bowel disease that includes Crohn's disease and ulcerative colitis. Kyverna Therapeutics, Inc. has a license and collaboration agreement with Intellia Therapeutics, Inc. to research and develop an allogeneic CD19-directed CAR cell therapy product; and with Kite to research and develop programs for the treatment, diagnosis, and prevention of autoimmune, inflammatory, and allogeneic stem cell transplant inflammatory diseases. The company was formerly known as BAIT Therapeutics, Inc. and changed its name to Kyverna Therapeutics, Inc. in October 2019. Kyverna Therapeutics, Inc. was incorporated in 2018 and is headquartered in Emeryville, California.
KYTX Stock 12 Month Forecast
Average Price Target
$29.50
▲(267.83% Upside)
Technical Analysis
Codexis
―
Heron Therapeutics
―
Silence Therapeutics
―
Atea Pharmaceuticals
―
Entrada Therapeutics Inc
―
Ownership Overview
24.63% Insiders
5.02% Mutual Funds
14.73% Other Institutional Investors
51.50% Public Companies and Individual Investors